Unknown

Dataset Information

0

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.


ABSTRACT:

Purpose

The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue.

Methods

In total, 2,472 samples were included in the building of the pharmacokinetic model. Farletuzumab 12.5-400 mg/m(2) had been administered via intravenous infusion to 79 patients with advanced ovarian cancer enrolled in one of the two clinical studies. Data were analyzed by a nonlinear mixed-effects modeling approach.

Results

Farletuzumab pharmacokinetics was best described by a two-compartment model with first-order (linear) elimination. In the final model, estimated values of clearance and volume of distribution of the central compartment were 0.00784 l/h and 3.00 l, respectively. Body weight was the only covariate investigated that explained inter-patient variability in clearance and the central volume of distribution. There was no effect of age, human anti-human antibodies, or concomitant chemotherapy on the pharmacokinetics of farletuzumab. Simulations showed that, when the mg/kg/week dose was maintained, steady-state exposure to farletuzumab was similar with dosing every week or every 3 weeks.

Conclusions

The pharmacokinetic parameters of farletuzumab are similar to those of other IgG mAbs. The results support weight-based dosing of farletuzumab on a weekly or 3-weekly schedule.

SUBMITTER: Farrell C 

PROVIDER: S-EPMC3485533 | biostudies-literature | 2012 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Population pharmacokinetics of farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer.

Farrell Colm C   Schweizer Charles C   Wustner Jason J   Weil Susan S   Namiki Masayuki M   Nakano Tomohisa T   Nakai Kenya K   Phillips Martin D MD  

Cancer chemotherapy and pharmacology 20120907 5


<h4>Purpose</h4>The purpose of this analysis was to develop a population pharmacokinetic model for farletuzumab, a humanized immunoglobulin (Ig)G(1) monoclonal antibody (mAb) to the folate receptor alpha, which is a receptor over-expressed in ovarian cancer, but largely absent from normal tissue.<h4>Methods</h4>In total, 2,472 samples were included in the building of the pharmacokinetic model. Farletuzumab 12.5-400 mg/m(2) had been administered via intravenous infusion to 79 patients with advanc  ...[more]

Similar Datasets

| S-EPMC4387250 | biostudies-literature
| S-EPMC6631954 | biostudies-literature
| S-EPMC3925658 | biostudies-literature
| S-EPMC1458527 | biostudies-literature
| S-EPMC3338945 | biostudies-literature
| S-EPMC3307324 | biostudies-literature
| S-EPMC5270291 | biostudies-literature
| S-EPMC7541015 | biostudies-literature
| S-EPMC8555527 | biostudies-literature
| S-EPMC6879217 | biostudies-literature